OTC Markets OTCPK - Delayed Quote USD
Universal Ibogaine Inc. (IBOGF)
0.0177
-0.0013
(-6.84%)
At close: 10:20:38 AM EDT
Breakdown
TTM
7/31/2024
7/31/2023
7/31/2022
7/31/2021
Total Revenue
1,896.0320
2,331.0280
1,029.9890
1,070.8040
--
Operating Expense
3,008.2010
3,232.1400
3,080.6850
5,817.0490
3,864.8860
Operating Income
-1,112.1690
-901.1120
-2,050.6960
-4,746.2450
-3,864.8860
Net Non Operating Interest Income Expense
-155.3720
-163.2610
-153.2240
-67.7420
-15.0050
Other Income Expense
-1,005.0300
-987.2140
-186.4910
-5,682.2150
12.6740
Pretax Income
-2,272.5710
-2,051.5870
-2,390.4110
-10,496.2020
-3,867.2170
Net Income Common Stockholders
-2,272.5710
-2,051.5870
-2,390.4110
-10,496.2020
-3,867.2170
Diluted NI Available to Com Stockholders
-2,272.5710
-2,051.5870
-2,390.4110
-10,496.2020
-3,867.2170
Basic EPS
-0.01
-0.01
-0.01
-0.06
-0.03
Diluted EPS
-0.01
-0.01
-0.01
-0.06
-0.03
Basic Average Shares
290,917.4880
232,502.7110
191,298.2570
185,636.8550
125,189.5970
Diluted Average Shares
290,917.4880
232,502.7110
191,298.2570
185,636.8550
125,189.5970
Total Operating Income as Reported
189.3990
551.6640
-28.0330
497.1510
--
Total Expenses
3,008.2010
3,232.1400
3,080.6850
5,817.0490
3,864.8860
Net Income from Continuing & Discontinued Operation
-2,272.5710
-2,051.5870
-2,390.4110
-10,496.2020
-3,867.2170
Normalized Income
-1,285.3570
-1,064.3730
-2,217.3020
-4,941.5640
-3,848.0690
Interest Income
--
5.6870
--
--
31.8220
Interest Expense
161.0590
168.9480
118.1290
67.7420
15.0050
Net Interest Income
-155.3720
-163.2610
-153.2240
-67.7420
-15.0050
EBIT
-2,111.5120
-1,882.6390
-2,272.2820
-10,428.4600
-3,852.2120
EBITDA
-1,764.0610
-1,539.1770
-1,976.2360
-10,162.0620
-3,782.3560
Reconciled Depreciation
347.4510
343.4620
296.0460
266.3980
69.8560
Net Income from Continuing Operation Net Minority Interest
-2,272.5710
-2,051.5870
-2,390.4110
-10,496.2020
-3,867.2170
Total Unusual Items Excluding Goodwill
-987.2140
-987.2140
-173.1090
-5,554.6380
-19.1480
Total Unusual Items
-987.2140
-987.2140
-173.1090
-5,554.6380
-19.1480
Normalized EBITDA
-776.8470
-551.9630
-1,803.1270
-4,607.4240
-3,763.2080
7/31/2021 - 3/1/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BCTXW BriaCell Therapeutics Corp.
0.1706
+36.48%
MDNAF Medicenna Therapeutics Corp.
0.7400
-2.50%
KALV KalVista Pharmaceuticals, Inc.
12.88
+3.45%
TARA Protara Therapeutics, Inc.
4.1100
-2.14%
LQDA Liquidia Corporation
14.03
+3.54%
URGN UroGen Pharma Ltd.
10.11
-0.88%
TLX Telix Pharmaceuticals Limited
19.22
+5.03%
CDIO Cardio Diagnostics Holdings, Inc.
0.5199
+13.69%
RIGL Rigel Pharmaceuticals, Inc.
19.06
+4.96%
IBO Impact BioMedical Inc.
0.4250
-0.19%